Pay in 4 interest-free payments of $5.63 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
doi:10.1155/2012/324832 Ma WH, Li M, Ma HF, et al
The FDA label specifies use for a few weeks as an adjunct to lifestyle changes
Precemtabart tocentecan (M9140), an anti-CEACAM5 ADC with exatecan payload, in patients with metastatic colorectal cancer: updated clinical data from the Phase 1 PROCEADE-CRC-01 study
Clear solution This protocol yields a clear solution of 1.25 mg/mL (saturation unknown)
Side effects are uncommon and mild, usually limited to minor warmth or redness at the injection site
US$ 26.39
US$ 29.91
US$ 24.78
US$ 26.70
US$ 25.70
.png)
US$ 23.08
US$ 24.61
US$ 28.36
